By Fineline Cube Salubris Pharmaceuticals (SHE: 002294) announced that its self‑developed innovative siRNA drug SAL0195 has been approved by China’s National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of elevated lipoprotein(a) [Lp(a)]. The candidate is designed as a highly potent and specific siRNA therapeutic targeting lipid‑lowering pathways.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Salubris (SHE: 002294) |
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval (IND) |
| Product | SAL0195 |
| Class | siRNA (small interfering RNA) drug |
| Indication | Elevated lipoprotein(a) [Lp(a)] |
| Approval Date | 08 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule: Self‑developed innovative siRNA (small interfering RNA) therapeutic
- Target: Lipoprotein(a) [Lp(a)] — an independent, genetically determined cardiovascular risk factor
- Mechanism: Highly potent and specific RNA interference (RNAi) that selectively knocks down hepatic expression of Lp(a), reducing circulating levels
- Formulation: Investigational siRNA drug
- Differentiator: Long‑acting target knockdown effect demonstrated in preclinical models
Preclinical Evidence
| Parameter | SAL0195 Result | Implication |
|---|---|---|
| Target Knockdown Duration | Up to 140 days following a single dose | Potential for quarterly or less frequent dosing |
| Species Model | Non‑human primate (monkey) | Translationally relevant for human pharmacodynamics |
| Potency | Highly potent and specific | Supports competitive positioning vs. other Lp(a)‑targeting agents |
| Safety (Preclinical) | Generally well tolerated | Supports progression to human trials |
In preclinical monkey models, SAL0195 demonstrated a long‑acting target knockdown effect lasting up to 140 days following a single dose, a pharmacodynamic profile that suggests the potential for infrequent dosing intervals in humans — a meaningful advantage in the lipid‑lowering space where adherence is a persistent challenge.
Market Impact & Outlook
- Lp(a) Landscape: Elevated Lp(a) affects roughly 1 in 5 people globally and is an independent risk factor for atherosclerotic cardiovascular disease, yet no approved therapies specifically target Lp(a) reduction. The market opportunity for a first‑in‑class or best‑in‑class Lp(a)‑lowering agent is substantial.
- siRNA Competitive Dynamics: Novartis’s pelacarsen (antisense oligonucleotide) and Amgen’s olpasiran (siRNA) are the most advanced Lp(a)‑targeting candidates globally, both in Phase 3. SAL0195 enters the race with a preclinical knockdown duration that rivals or exceeds reported profiles of competitors, potentially supporting a differentiated dosing regimen.
- Salubris Pipeline Inflection: SAL0195 represents Salubris’s entry into the RNA therapeutics space, a strategic pivot beyond its established cardiovascular small‑molecule franchise. The NMPA green light triggers a Phase 1 dosing program in China, with potential for global expansion.
- Revenue Forecast: Analysts project the global Lp(a)‑targeted therapy market could reach $5–8 billion annually by the early 2030s if cardiovascular outcome trials demonstrate event reduction. A domestically developed siRNA with quarterly dosing could capture meaningful share in China and emerging markets.
- Next Steps: Salubris is expected to initiate Phase 1 first‑in‑human studies in China in late 2026 or early 2027, with initial pharmacodynamic readouts anticipated in H2 2027.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory timeline, and commercial potential of SAL0195. Actual results may differ materially due to risks including clinical trial outcomes, manufacturing scale‑up, regulatory requirements, competitive dynamics, and market acceptance. The NMPA clinical trial approval does not guarantee marketing authorization. Investors should consult official filings for updated risk factors.-Fineline Info & Tech